Long-term survival of women with basal-like ductal carcinoma in situ of the breast: A population-based cohort study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Zhou, Wenjing ^a   Jirström, Karin ^b   Johansson, Christine ^a   Amini, Rose Marie ^a   Blomqvist, Carl ^c   Agbaje, Olorunsola ^d   Wärnberg, Fredrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; PARTIAL MASTECTOMY; POPULATION RESEARCH; PROGNOSIS; SURVIVAL TIME; SWEDEN; BREAST TUMOR; CHEMISTRY; CHI SQUARE DISTRIBUTION; GENETICS; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; STATISTICS; SURVIVOR; TIME; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; SWEDEN; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78649453089     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-653     Document Type: Article

References (40)

1. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC cancer 2007, 7:55.
2. Tsikitis VL, Chung MA. Biology of ductal carcinoma in situ classification based on biologic potential. American journal of clinical oncology 2006, 29(3):305-310. 10.1097/01.coc.0000198740.33617.2f, 16755185.
3. Namba R, Maglione JE, Davis RR, Baron CA, Liu S, Carmack CE, Young LJ, Borowsky AD, Cardiff RD, Gregg JP. Heterogeneity of mammary lesions represent molecular differences. BMC cancer 2006, 6:275. 10.1186/1471-2407-6-275, 1762020, 17147824.
4. Zhao J, Liu H, Wang M, Gu L, Guo X, Gu F, Fu L. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol 2009, 100(2):89-94. 10.1002/jso.21307, 19544363.
5. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 2009, 20(4):628-635. 10.1093/annonc/mdn675, 19074747.
6. Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat 2009,
7. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009, 113(2):357-370. 10.1007/s10549-008-9926-3, 18324472.
8. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10(4):R65.. 10.1186/bcr2124, 2575538, 18662380.
9. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270(5235):467-470. 10.1126/science.270.5235.467, 7569999.
10. Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(11):5022-5026. 10.1073/pnas.91.11.5022, 43922, 8197176.
11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
12. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-Dale AL. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006, 7:127. 10.1186/1471-2164-7-127, 1489944, 16729877.
13. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(19):10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
14. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(14):8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
15. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(18):10393-10398. 10.1073/pnas.1732912100, 193572, 12917485.
16. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 2005, 69(6):478-485. 10.1159/000090986, 16410686.
17. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-2502. 10.1001/jama.295.21.2492, 16757721.
18. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007, 38(2):197-204. 10.1016/j.humpath.2006.08.017, 17234468.
19. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
20. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 2006, 59(7):729-735. 10.1136/jcp.2005.033043, 1860434, 16556664.
21. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14(5):1368-1376. 10.1158/1078-0432.CCR-07-1658, 18316557.
22. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19(2):264-271. 10.1038/modpathol.3800528, 16341146.
23. Warnberg F, Amini RM, Goldman M, Jirstrom K. Quality aspects of the tissue microarray technique in a population-based cohort with ductal carcinoma in situ of the breast. Histopathology 2008, 53(6):642-649. 10.1111/j.1365-2559.2008.03156.x, 19076680.
24. Jirstrom K, Ringberg A, Ferno M, Anagnostaki L, Landberg G. Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer 2003, 89(10):1920-1926. 10.1038/sj.bjc.6601398, 2394433, 14612904.
25. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Ferno M, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007, 9(1):R16.. 10.1186/bcr1649, 1851391, 17263897.
26. Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 2007, 14(10):2994-3003. 10.1245/s10434-007-9477-6, 17647064.
27. Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 2006, 45(5):536-543. 10.1080/02841860600681569, 16864166.
28. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005, 116(3):340-350. 10.1002/ijc.21004, 15818618.
29. Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?. Hum Pathol 2008, 39(4):506-513. 10.1016/j.humpath.2007.09.005, 18289638.
30. Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?. Diagn Mol Pathol 2009, 18(3):125-132. 10.1097/PDM.0b013e31818d107b, 19704256.
31. Francis GD, Jones MA, Beadle GF, Stein SR. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 2009, 18(2):88-95. 10.1097/PDM.0b013e31816f6374, 19430296.
32. Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Histopathology 2009, 54(2):248-253. 10.1111/j.1365-2559.2008.03185.x, 19207950.
33. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD, DeWitty RL, Frederick WA. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg 2008, 247(3):463-469. 10.1097/SLA.0b013e31815d744a, 18376191.
34. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007, 16(3):439-443. 10.1158/1055-9965.EPI-06-0806, 17372238.
35. http://www.swebcg.se/index.asp?P=NatRikt
36. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res 2009, 7(1-2):4-13. 10.3121/cmr.2009.825, 2705275, 19574486.
37. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, Bois AD. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009,
38. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009,
39. Thike AA, Iqbal J, Cheok PY, Chong AP, Tse GM, Tan B, Tan P, Wong NS, Tan PH. Triple Negative Breast Cancer: Outcome Correlation With Immunohistochemical Detection of Basal Markers. Am J Surg Pathol
40. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA et A. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15(7):2302-2310. 10.1158/1078-0432.CCR-08-2132, 19318481.